WO2011036561A2 - Process - Google Patents
Process Download PDFInfo
- Publication number
- WO2011036561A2 WO2011036561A2 PCT/IB2010/002543 IB2010002543W WO2011036561A2 WO 2011036561 A2 WO2011036561 A2 WO 2011036561A2 IB 2010002543 W IB2010002543 W IB 2010002543W WO 2011036561 A2 WO2011036561 A2 WO 2011036561A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organic solvent
- methylthioninium chloride
- pentahydrate form
- water
- drying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a process for the preparation of substantially pure methylthioninium chloride pentahydrate Form A.
- the present invention also relates to the use of the so prepared Form A, preferably in pharmaceutical compositions.
- Methylthioninium chloride [Methylene Blue: 3,7-bisdimethylaminophenazothionium chloride, C 16 H 18 CIN 3 S, 319.85 g/mol] was prepared for the first time in 1876 (The Merck Index, 13 th edition, Merck & Co., Inc., 2001 , entry 6085).
- Various synthesis methods are known and have recently been summarized in WO 2006/032879. This publication describes in example 16 a re-crystallization of MTC from a water solution by adding tetrahydrofuran and drying of the isolated solid at a temperature of 100°C, not suitable to avoid dehydration of MTC pentahydrate.
- WO 2006/032879 also states a number of applications of methylene blue, which include the use as a medical dye, as a redox indicator, an antiseptic, for the treatment and prevention of kidney stones, the treatment of melanoma, malaria, viral infections, and Alzheimer's disease.
- MTC has also been used as an oxidizing agent and as an antidote in the case of CO, nitrite and aniline poisoning.
- MTC is known to exist in the form of hydrates.
- the Fluka catalogue states in very general terms that MTC may contain up to 22% water [Fluka Catalogue 1997/1998, Fluka Chemie AG, 1997]. Structures with from one to five molecules of water have been formulated in the literature [J.O. Warwicker, J.
- MTC is typically obtained by re-crystallization from aqueous solutions, whereby NaCI or HCI may be added to lower its solubility [W.H. Taylor, 2. Krist. 91 (1935) 450; J.O. Warwicker, J. Chem. Soc. (1955) 2531 ; H.E: Fierz-David, L. Blangey, Fundamental Processes of Dye Chemistry, Interscience, New York, 1949, p. 3111-314].
- the product of the re-crystallization contains noticeable amounts of excess water, which requires a subsequent drying step. Investigations have shown that it is difficult to obtain a product of well defined stoichiometry, such as a pure MTC pentahydrate Form A, by this purification process.
- thermodynamic stability of hydrates is always a function of temperature and relative humidity. Exposing a hydrate to temperature and relative humidity conditions outside its stability domain may result in its transformation into other forms.
- the solid state form of a compound is of great importance for pharmaceutical applications. It may influence the chemical and physical stability of the compound itself and of its
- compositions may have an impact on pharmacokinetics and bioavailability.
- the composition has also an influence on the correct dosage of the active pharmaceutical ingredient.
- the present invention provides a safe and reproducible process for the preparation of substantially pure methylthioninium chloride pentahydrate Form A, which can be applied in an industrial manufacture.
- the present invention further provides a process, which results in a Form A content of at least 95% by weight, preferably at least 98%, most preferred at least 99% based on the total weight of methylthioninium chloride.
- the present invention also provides a storage stable methylthioninium chloride which is substantially pure
- methylthioninium chloride pentahydrate Form A which can be easily metered for a defined content in pharmaceutical compositions.
- the present invention also provides a storage stable methylthioninium chloride having a Form A content of at least 95% by weight, preferably at least 98%, most preferred at least 99% based on the total weight of
- a first aspect of the invention is a process for the preparation of substantially pure
- a) methylthioninium chloride is suspended in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, the suspension is kept at low temperature, and the solid is isolated and dried to remove the organic solvent and any excess water from the solid;
- methylthioninium chloride is dissolved at elevated temperatures in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, the solution is cooled, the precipitated solid is isolated and dried to remove the solvent and any excess water from the solid; or
- methylthioninium chloride is dissolved in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, and the solvent and any excess water is evaporated to dryness of the solid.
- substantially pure refers to methylthionium chloride having a Form A content of at least 95% by weight, preferably at least 98%, most preferred at least 99% based on the total weight of methylthioninium chloride.
- Methylthioninium chloride may as starting material consist of a water-free or a water containing MTC comprising e.g. from 0.1 to 22 percent by weight of water, based on the total weight of the starting material.
- Methylthioninium chloride may be in the form of a hydrate or an arbitrary mixture of hydrates.
- MTC as prepared according to WO 2006/032879 may be used (e.g. example 17). It is advantageous to know the total water content of the starting material so that it can be taken into account for the calculation of the water activity in the solvent composition.
- the water content can be determined by thermogravimetry or Karl Fischer titration.
- the progress of the conversion may be followed by appropriate analytical methods such as thermogravimetry, differential scanning calorimetry, infrared spectroscopy or X-ray powder diffraction.
- a particularly suitable method is X-ray powder diffraction, which provides characteristic signals for TC pentahydrate Form A independently of the presence of residual organic solvent.
- the organic solvent which includes a mixture of at least two organic solvents, preferably possesses a poor solubility for MTC pentahydrate Form A at the temperature of isolation of the crystalline product, which is typically at room temperature or below.
- Solubility for MTC pentahydrate Form A is influenced by increased temperature and/or presence of water.
- a solubility of less than 20 g/l and in particular less than 2 g/l at room temperature is preferred for process variants a) and b).
- the organic solvent is preferably miscible with water.
- the vapor pressure of the organic solvent preferably exceeds the one of water.
- Particularly suitable solvents include methanol, ethanol, 1-propanol, 2-propanol, 2-methyl-2-propanol, acetonitrile, tetrahydrofurane, 1,4-dioxane and acetone and mixtures thereof.
- Particularly preferred solvents for process variants a) and b) include 1-propanol, tetrahydrofurane and acetone and mixtures thereof.
- Particularly preferred solvents for process variant c) include methanol and ethanol and mixtures thereof The water content is chosen in such a way that the thermodynamic stability of MTC pentahydrate Form A is given up to the end of the process.
- thermodynamic stability can be determined experimentally, for example by determining the water content of a solution that is in equilibrium with a mixture of methylthioninium pentahydrate Form A and the hydrate that is thermodynamically stable at lower water activity. For this purpose, the composition of a water/solvent mixture of a suspension of methylthioninium pentahydrate Form A may be changed until a mixture of the two polymorphic forms in question is detected in the solid. The water content in solution may then be determined e.g. by Karl-Fischer titration. Based on such an experiment, at 25°C, thermodynamic stability of MTC pentahydrate Form A is given for a water activity of 0.4 or higher, i.e.
- the water content is preferably chosen in such a way that complete solubility of MTC pentahydrate Form A is achieved at the maximum temperature of the crystallization step and a sufficiently low solubility is given at the minimum temperature of the crystallization step in order to ensure high yields of MTC pentahydrate Form A.
- the water content of the liquid phase preferably does not exceed 50 wt.-%, based on the liquid phase, more preferably does not exceed 20 wt.-%, and most preferably does not exceed 10 wt.-%.
- Low temperature in process variant a) may mean in the context of the invention a
- Temperature cycles within this temperature range may be applied during this phase equilibration process.
- phase equilibration process a) and the crystallization processes b) and c) may be carried out under stirring.
- Dissolution of the starting material in process variant b) may be carried out under heating up to the reflux temperature of the solvent, preferably to 40 to 100°C, which means in the context of the invention elevated temperature. Cooling of the hot solution may be carried out continuously or in steps. Seeding with nucleating agents such as MTC Form A crystals may be advantageous.
- the suspension according to process variant a) has to be equilibrated for sufficiently long time to insure complete conversion.
- the required time will depend on the solids content, particle size, temperature and water concentration.
- an equilibration time of from hours to several days is sufficient. The progress of the conversion may be followed as described before.
- the organic solvent or solvent mixture used in process variant c) has to have a reasonably high dissolving power for the starting material, either by itself or in combination with water.
- the solubility of MTC pentahydrate Form A is preferably higher than 20 g/l at room temperature, especially preferred higher than 50 g/l, and most preferred higher than 100 g/l.
- the vapor pressure of the organic solvent or solvent mixture preferably exceeds the one of water.
- Process variant c) preferably uses starting materials which already have an appropriate chemical purity, since no purification is involved in this process c) contrary to re-crystallization (process variant b) or phase equilibration (process variant a).
- Water activity in process variant c) may either be provided as water in the liquid phase or by evaporation at sufficiently high relative humidity.
- the required water activity in solution or the relative humidity of the gas phase is given by the thermodynamic stability limits of MTC pentahydrate form A. This stability limit amounts to about at least 40% r.h. at 25°C and increases to higher values at higher temperatures.
- a temperature close to room temperature is preferred for the evaporation process in order to have a broad stability window of MTC pentahydrate Form A available.
- Evaporation of solvent according to process variant c) is preferably carried out at low temperature such as 10 to 30°C and a relative humidity of preferably 40 to 80%.
- the solution is stored under ambient conditions to let slowly evaporate the solvent.
- a humidified inert gas flow such as a nitrogen or noble gas flow may be applied to accelerate solvent evaporation.
- the starting amount of methylthioninium chloride hydrates in the process variants a), b) or c) according to the invention may range from 0.1 to 60 % by weight, preferably 1 to 50% by weight and more preferably 5 to 40 % by weight, based on the total weight of the suspension or solution.
- Isolation of the solid MTC pentahydrate Form A is typically achieved by decantation and preferably by filtration.
- Drying of said methylthioninium chloride pentahydrate Form A must be controlled within its stability ranges of humidity, vacuum and temperature.
- Drying is intended for the selective removal of excess water and especially solvent. It may be performed by either passing a humidified gas flow over the sample or by vacuum drying,
- the required relative humidity of the gas flow and the appropriate minimum pressure for vacuum drying depend on the temperature and may be estimated from dynamic vapor sorption experiments. In this type of experiment, the sample under investigation is exposed to a humidified gas flow with a steadily changing relative humidity at constant temperature. The weight of the sample is determined at short time intervals, which permits to detect a change in the hydration state. Dynamic vapor sorption curves give an approximate indication of the kinetic stability domain of a hydrate. According to such measurements, MTC pentahydrate Form A is kinetically stable down to approximately 15% relative humidity at 25°C and approximately 30% relative humidity at 40°C.
- Preferred conditions to carry out the process variants according to the invention are: isolation of the product at a temperature not higher than 40°C, preferably not higher than 30°C, and most preferred not higher than 25°C; removal of excess solvent and excess water by vacuum drying or in a flow of humid inert gas; performing vacuum drying at a temperature not higher than 40°C and a pressure not lower than 20 mbar, preferably at a temperature not higher than 25°C and a pressure not lower than 5 mbar; performing drying with an inert gas flow at a temperature not higher than 40°C and at a relative humidity of the gas not below 30%, preferably at a temperature not higher than 25°C and at a relative humidity of the gas not below 15%.
- Substantially pure Methylthioninium chloride pentahydrate Form A is obtained in high yields and good crystallinity.
- the kinetic and thermodynamic stability of substantially pure Form A provides easy and safe handling and processing under the described stability conditions without conversion to other crystalline forms or dehydration, ensuring preparation of storage stable, well dosed compositions, preferably pharmaceutical formulations.
- Form A is thought to be stable at high relative humidity down to about 35 % r.h. or 40% r.h.
- Form A is also stable at 25°C.
- a further aspect of the present invention relates to the drying of MTC pentahydrate Form A to remove excess water and/or solvent either by vacuum drying or by drying in a flow of humid insert gas, such as nitrogen.
- the conditions should be such that the MTC pentahydrate form A is not dehydrated.
- This drying should be carried out a temperature not higher than 40°C.
- the drying is carried out a temperature not higher than 30°C or even 25°C. If the drying is carried out by vacuum drying, the vacuum should be greater than or equal to 60 mbar.
- the relative humidity of the gas should be adjusted so as not to dehydrate the MTC pentahydrate form A. In some embodiments, the relative humidity should not be below 30%. However, in further embodiments, whilst if the drying is carried out at 40°C, the relative humidity of the gas should not below 30%, if the drying is carried out at 25°C, then the relative humidity of the gas can be lower, but should not below 15%.
- a further aspect of the present invention provides substantially pure methylthioninium chloride pentahydrate Form A which is obtained by, or is obtainable by, the methods described above.
- compositions comprising substantially pure MTC pentahydrate Form A which is obtained by, or is obtainable by, a method as described herein.
- the composition further comprises a pharmaceutically acceptable carrier, diluent, or excipient.
- One aspect of the present invention pertains to use of substantially pure MTC pentahydrate Form A, which is obtained by, or is obtainable by, a method as described herein, in a method of inactivating a pathogen in a sample (for example a blood or plasma sample), the method comprising introducing the compound into the sample, and exposing the sample to light.
- a sample for example a blood or plasma sample
- One aspect of the present invention pertains to substantially pure MTC pentahydrate Form A, which is obtained by, or is obtainable by, a method as described herein, for use in a method of treatment (e.g., of a disease condition) of the human or animal body by therapy.
- One aspect of the present invention pertains to use of substantially pure MTC pentahydrate Form A, which is obtained by, or is obtainable by, a method as described herein, for the manufacture of a medicament for use in the treatment of a disease condition.
- One aspect of the present invention pertains to use of substantially pure MTC pentahydrate Form A, which is obtained by, or is obtainable by, a method as described herein, in the treatment of a disease condition.
- One aspect of the present invention pertains to a method of treatment of a disease condition in a patient, comprising administering to said patient a therapeutically-effective amount of substantially pure MTC pentahydrate Form A, which is obtained by, or is obtainable by, a method as described herein.
- the disease condition is a tauopathy.
- tauopathy is a condition in which tau protein (and aberrant function or processing thereof) plays a role.
- Alzheimer's Disease is an example of a tauopathy.
- the pathogenesis of neurodegenerative disorders such as Pick's disease and Progressive Supranuclear Palsy (PSP) appears to correlate with an accumulation of pathological truncated tau aggregates in the dentate gyrus and stellate pyramidal cells of the neocortex, respectively.
- PSP Progressive Supranuclear Palsy
- AD fronto-temporal dementia
- FTDP-17 parkinsonism linked to chromosome 17
- DDPAC disinhibition-dementia-parkinsonism- amyotrophy complex
- PPND pallido- ponto-nigral degeneration
- PNLD pallido-nigro-luysian degeneration
- CBD cortico-basal degeneration
- the disease condition is Alzheimer's disease (AD).
- AD Alzheimer's disease
- the disease condition is skin cancer.
- the disease condition is melanoma.
- the disease condition is viral, bacterial or protozoal.
- the protozoal disease condition is malaria.
- treatment may be in combination with another antimicrobial agent e.g. in combination with chloroquine or atovaquone.
- the viral disease condition is caused by Hepatitis C, HIV or West Nile virus.
- treatment pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition.
- Treatment as a prophylactic measure i.e., prophylaxis, prevention is also included.
- terapéuticaally-effective amount pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
- treatment includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
- treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; and gene therapy.
- active agents including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; and gene therapy.
- Substantially pure MTC pentahydrate Form A may be administered to a subject/patient by any convenient route of administration, whether systemically/peripherally or topically (i.e., at the site of desired action).
- Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary);
- parenteral for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrastemal (including, e.g., intracatheter injection into the brain); by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.
- the subject/patient may be an animal, mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus), a rodent
- a guinea pig e.g., a guinea pig, a hamster, a rat, a mouse
- murine e.g., a mouse
- a lagomorph e.g., a rabbit
- avian e.g., a bird
- canine e.g., a dog
- feline e.g., a cat
- equine e.g., a horse
- porcine e.g., a pig
- ovine e.g., a sheep
- bovine e.g., a cow
- a primate simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human.
- the subject/patient may be any of its forms of development, for example, a foetus.
- the subject/patient is a human.
- the composition is a pharmaceutical composition (e.g., formulation, preparation, medicament) comprising substantially pure MTC pentahydrate Form A, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- a pharmaceutical composition e.g., formulation, preparation, medicament
- substantially pure MTC pentahydrate Form A as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
- the composition is a pharmaceutical composition comprising at least substantially pure MTC pentahydrate Form A, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.
- pharmaceutically acceptable carriers diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.
- the composition further comprises other active agents, for example, other therapeutic or prophylactic agents.
- Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts. See, for example, Handbook of Pharmaceutical Additives, 2nd Edition (eds. M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA), Remington's Pharmaceutical Sciences, 20th edition, pub. Lippincott, Williams & Wilkins, 2000; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.
- Another aspect of the present invention pertains to methods of making a pharmaceutical composition
- a pharmaceutical composition comprising admixing substantially pure [ 1 C]-radiolabelled MTC pentahydrate Form A, as defined herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the active compound.
- pharmaceutically acceptable pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- the formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with a carrier which constitutes one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association the active compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.
- carriers e.g., liquid carriers, finely divided solid carrier, etc.
- the formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.
- Formulations suitable for parenteral administration include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the active ingredient is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate).
- sterile liquids e.g., solutions, suspensions
- Such liquids may additional contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers,
- bacteriostats suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient.
- excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like.
- suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
- concentration of the active ingredient in the liquid is from about 1 ng/ml to about 10 pg/ml, for example from about 10 ng/ml to about 1 pg/ml.
- the formulations may be presented in unit- dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- sterile liquid carrier for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- One aspect of the present invention pertains to a dosage unit (e.g., a pharmaceutical tablet or capsule) comprising 20 to 300 mg of substantially pure MTC pentahydrate form A obtained by, or obtainable by, a process as described herein and a pharmaceutically acceptable carrier, diluent, or excipient.
- a dosage unit e.g., a pharmaceutical tablet or capsule
- 20 to 300 mg of substantially pure MTC pentahydrate form A obtained by, or obtainable by, a process as described herein and a pharmaceutically acceptable carrier, diluent, or excipient.
- the dosage unit is a tablet.
- the dosage unit is a capsule. In one embodiment, the amount is 20 to 200 mg.
- the amount is about 20 mg.
- the amount is about 60 mg.
- the amount is about 100 mg.
- the amount is about 150 mg.
- the amount is about 200 mg.
- the pharmaceutically acceptable carrier, diluent, or excipient is or comprises one or both of a glyceride (e.g., Gelucire 44/14 ®; lauroyl macrogol-32 glycerides PhEur, USP) and colloidal silicon dioxide (e.g., 2% Aerosil 200 ®; Colliodal Silicon Dioxide PhEur, USP).
- a glyceride e.g., Gelucire 44/14 ®; lauroyl macrogol-32 glycerides PhEur, USP
- colloidal silicon dioxide e.g., 2% Aerosil 200 ®; Colliodal Silicon Dioxide PhEur, USP
- pentahydrate form A can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of
- the amount of compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
- a suitable dose of substantially pure MTC pentahydrate form A is in the range of about 100 ng to about 25 mg (more typically about 1 pg to about 10 mg) per kilogram body weight of the subject per day.
- substantially pure MTC pentahydrate form A is administered to a human patient according to the following dosage regime: about 100 mg, 3 times daily. In one embodiment, substantially pure MTC pentahydrate form A is administered to a human patient according to the following dosage regime: about 150 mg, 2 times daily.
- substantially pure MTC pentahydrate form A is administered to a human patient according to the following dosage regime: about 200 mg, 2 times daily.
- room temperature corresponds to 25 °C and ambient conditions correspond to room temperature and a pressure of 1 ,013 bar.
- ambient conditions correspond to room temperature and a pressure of 1 ,013 bar.
- Starting materials are prepared according to examples described in WO 2006/032879 having various water contents corresponding to a lower water content than methylthioninium chloride pentahydrate.
- Powder X-ray Diffraction is performed on a Bruker D8 Advance powder X-ray diffractometer using CuKa radiation. D-spacings are calculated from the 2 ⁇ values using the wavelength of 1.54180 A. Generally, 2 ⁇ values are within an error of ⁇ 0.1 -0.2°. The experimental error on the d-spacing values is therefore dependent on the peak location.
- Methylthioninium chloride pentahydrate form A preferably exhibits the following characteristic 2 ⁇ values ( ⁇ 0.1 °): 5.7, 9.2, 9.6, 10.8, 18.7, 19.3, 25.6, 26.0, 26.2, 26.4, 27.3, 28.0 and 28.4.
- Methylthioninium chloride pentahydrate form A most preferably exhibits the following characteristic 2 ⁇ values ( ⁇ 0.1 °): 5.7, 9.2, 9.6, 10.8, 1 1.3, 18.7, 19.3, 20.4, 21.7, 21.9, 24.6, 25.6, 26.0, 26.2, 26.4, 27.3, 28.0, 28.4 and 29.2.
- pentahydrate Form A are obtained as confirmed by X-ray powder diffraction.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/497,691 US8901296B2 (en) | 2009-09-24 | 2010-09-23 | Process for the preparation of substantially pure methylthionium chloride pentahydrate form A |
BR112012006626A BR112012006626B8 (en) | 2009-09-24 | 2010-09-23 | process for the preparation of form a pentahydrate and method of drying form a pentahydrate of mtc |
PL10771180T PL2480540T3 (en) | 2009-09-24 | 2010-09-23 | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof |
DK10771180.6T DK2480540T3 (en) | 2009-09-24 | 2010-09-23 | METHYLTHIONINIUM CHLORIDE PENTA HYDRATE, PREPARATION AND PHARMACEUTICAL APPLICATION THEREOF |
CA2773306A CA2773306C (en) | 2009-09-24 | 2010-09-23 | Process for the preparation of substantially pure methylthioninium chloride pentahydrate form a |
EP10771180.6A EP2480540B1 (en) | 2009-09-24 | 2010-09-23 | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof |
KR1020127009858A KR101728574B1 (en) | 2009-09-24 | 2010-09-23 | Process for the preparation of substantially pure methylthioninium chloride pentahydrate form a |
ES10771180.6T ES2659091T3 (en) | 2009-09-24 | 2010-09-23 | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof |
CN201080053177.8A CN102666510B (en) | 2009-09-24 | 2010-09-23 | The preparation method and its usage of essentially pure methylene blue pentahydrate form A |
SI201031633T SI2480540T1 (en) | 2009-09-24 | 2010-09-23 | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof |
JP2012530358A JP5918136B2 (en) | 2009-09-24 | 2010-09-23 | process |
AU2010299574A AU2010299574B2 (en) | 2009-09-24 | 2010-09-23 | Process |
MX2012003035A MX2012003035A (en) | 2009-09-24 | 2010-09-23 | Process. |
HRP20180347TT HRP20180347T1 (en) | 2009-09-24 | 2018-02-26 | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24537209P | 2009-09-24 | 2009-09-24 | |
US61/245,372 | 2009-09-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011036561A2 true WO2011036561A2 (en) | 2011-03-31 |
WO2011036561A3 WO2011036561A3 (en) | 2011-05-19 |
WO2011036561A8 WO2011036561A8 (en) | 2012-04-19 |
Family
ID=43662090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/002543 WO2011036561A2 (en) | 2009-09-24 | 2010-09-23 | Process |
Country Status (17)
Country | Link |
---|---|
US (1) | US8901296B2 (en) |
EP (1) | EP2480540B1 (en) |
JP (2) | JP5918136B2 (en) |
KR (1) | KR101728574B1 (en) |
CN (1) | CN102666510B (en) |
AU (1) | AU2010299574B2 (en) |
BR (1) | BR112012006626B8 (en) |
CA (1) | CA2773306C (en) |
DK (1) | DK2480540T3 (en) |
ES (1) | ES2659091T3 (en) |
HR (1) | HRP20180347T1 (en) |
MX (1) | MX2012003035A (en) |
MY (1) | MY161463A (en) |
PL (1) | PL2480540T3 (en) |
PT (1) | PT2480540T (en) |
SI (1) | SI2480540T1 (en) |
WO (1) | WO2011036561A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130243858A1 (en) * | 2010-11-30 | 2013-09-19 | Wista Laboratories Ltd. | Compound formulations |
WO2018019823A1 (en) | 2016-07-25 | 2018-02-01 | Wista Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
WO2018041739A1 (en) | 2016-09-01 | 2018-03-08 | Wista Laboratories Ltd. | Treatment of dementia |
WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
WO2024061971A1 (en) | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005502861A (en) * | 2001-08-10 | 2005-01-27 | サイミックス テクノロジーズ, インコーポレイテッド | Apparatus and method for making and testing pre-formulations and system therefor |
CN101084204B (en) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
PL2013191T6 (en) * | 2006-03-29 | 2019-07-31 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
FI3792254T3 (en) * | 2009-09-24 | 2023-09-22 | Wista Lab Ltd | Crystalline methylthioninium chloride hydrates |
-
2010
- 2010-09-23 KR KR1020127009858A patent/KR101728574B1/en active IP Right Grant
- 2010-09-23 CA CA2773306A patent/CA2773306C/en active Active
- 2010-09-23 PL PL10771180T patent/PL2480540T3/en unknown
- 2010-09-23 ES ES10771180.6T patent/ES2659091T3/en active Active
- 2010-09-23 US US13/497,691 patent/US8901296B2/en active Active
- 2010-09-23 JP JP2012530358A patent/JP5918136B2/en active Active
- 2010-09-23 BR BR112012006626A patent/BR112012006626B8/en active IP Right Grant
- 2010-09-23 CN CN201080053177.8A patent/CN102666510B/en active Active
- 2010-09-23 PT PT107711806T patent/PT2480540T/en unknown
- 2010-09-23 DK DK10771180.6T patent/DK2480540T3/en active
- 2010-09-23 MY MYPI2012001321A patent/MY161463A/en unknown
- 2010-09-23 SI SI201031633T patent/SI2480540T1/en unknown
- 2010-09-23 EP EP10771180.6A patent/EP2480540B1/en active Active
- 2010-09-23 MX MX2012003035A patent/MX2012003035A/en active IP Right Grant
- 2010-09-23 AU AU2010299574A patent/AU2010299574B2/en active Active
- 2010-09-23 WO PCT/IB2010/002543 patent/WO2011036561A2/en active Application Filing
-
2015
- 2015-11-24 JP JP2015228627A patent/JP2016074699A/en active Pending
-
2018
- 2018-02-26 HR HRP20180347TT patent/HRP20180347T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
Non-Patent Citations (15)
Title |
---|
"Handbook of Pharmaceutical Additives", 2001, SYNAPSE INFORMATION RESOURCES, INC. |
"Handbook of Pharmaceutical Excipients", 1994 |
"Pharmaceutical Sciences", 2000, LIPPINCOTT, WILLIAMS & WILKINS |
"The Merck Index", 2001, MERCK & CO., INC., pages: 6085 |
C.M. MARTIN; J.W.G. NEUHAUS; F.H. REUTER, ANALYST, vol. 71, 1946, pages 29 - 31 |
D.R. LIDE: "CRC handbook of chemistry and physics", 1999, CRC PRESS, pages: 6 - 10 |
D.R. LIDE; H.V. KEHIAIAN: "CRC handbook of thermophysical and thermochemical data", 1994, CRC PRESS |
G.F. DAVIDSON, J. TEXTILE INSTITUTE, vol. 38, 1947, pages 408 - 418 |
H. WALES; O.A. NELSON, J. AM. CHEM. SOC., vol. 45, 1923, pages 1657 |
H.E. MARR III; J.M. STEWART; M.F. CHIU, ACTA CRYST, vol. 829, 1973, pages 847 |
H.E: FIERZ-DAVID; L. BLANGEY, FUNDAMENTAL PROCESSES OF DYE CHEMISTRY, INTERSCIENCE, 1949, pages 3111 - 314 |
J. GMEHLING; U. ONKEN; W. ARLT; P. GRENZHEUSER; U. WEIDLICH; B. KOLBE; J. RAREY-NIES: "Vapor-Liquid Equilibrium Data Collection", DECHEMA, pages 1978 - 1992 |
J.O. WARWICKER, J. CHEM. SOC., 1955, pages 2531 |
S.W. BODMAN; S.P. KODAMA; P.C. PFEIL; R.E. STEVENS, J. CHEM. ENG., vol. 12, 1967, pages 500 |
WISCHIK, C.M.; THEURING, F.; HARRINGTON, C.R.: "Neurobiology of Alzheimer's Disease", 2000, OXFORD UNIVERSITY PRESS, article "The molecular basis of tau protein pathology in Alzheimer's disease and related neurodegenerative dementias", pages: 103 - 206 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130243858A1 (en) * | 2010-11-30 | 2013-09-19 | Wista Laboratories Ltd. | Compound formulations |
US9192611B2 (en) * | 2010-11-30 | 2015-11-24 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
AU2011334679B2 (en) * | 2010-11-30 | 2016-12-15 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
WO2018019823A1 (en) | 2016-07-25 | 2018-02-01 | Wista Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
EP4223297A2 (en) | 2016-07-25 | 2023-08-09 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
EP4335517A2 (en) | 2016-07-25 | 2024-03-13 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
WO2018041739A1 (en) | 2016-09-01 | 2018-03-08 | Wista Laboratories Ltd. | Treatment of dementia |
US10842796B2 (en) | 2016-09-01 | 2020-11-24 | Wista Laboratories Ltd. | Treatment of dementia |
WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
WO2024061971A1 (en) | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
Also Published As
Publication number | Publication date |
---|---|
JP5918136B2 (en) | 2016-05-18 |
WO2011036561A3 (en) | 2011-05-19 |
HRP20180347T1 (en) | 2018-04-06 |
CA2773306C (en) | 2018-04-24 |
EP2480540B1 (en) | 2017-11-29 |
JP2016074699A (en) | 2016-05-12 |
PL2480540T3 (en) | 2018-05-30 |
AU2010299574B2 (en) | 2013-09-26 |
WO2011036561A8 (en) | 2012-04-19 |
KR101728574B1 (en) | 2017-04-19 |
DK2480540T3 (en) | 2018-01-22 |
CN102666510B (en) | 2016-09-14 |
CA2773306A1 (en) | 2011-03-31 |
CN102666510A (en) | 2012-09-12 |
PT2480540T (en) | 2018-02-16 |
US8901296B2 (en) | 2014-12-02 |
KR20120099410A (en) | 2012-09-10 |
ES2659091T3 (en) | 2018-03-13 |
BR112012006626B8 (en) | 2021-05-25 |
MY161463A (en) | 2017-04-14 |
BR112012006626B1 (en) | 2021-04-20 |
SI2480540T1 (en) | 2018-03-30 |
US20120289499A1 (en) | 2012-11-15 |
EP2480540A2 (en) | 2012-08-01 |
JP2013505926A (en) | 2013-02-21 |
MX2012003035A (en) | 2012-06-12 |
BR112012006626A2 (en) | 2016-05-03 |
AU2010299574A1 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3004822C (en) | Crystalline methylthioninium chloride hydrates | |
EP2480540B1 (en) | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof | |
AU2017228644B2 (en) | Crystalline methylthionium chloride (methylene blue) hydrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080053177.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10771180 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010299574 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2773306 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012530358 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/003035 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 666/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13497691 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010299574 Country of ref document: AU Date of ref document: 20100923 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2010771180 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010771180 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127009858 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012006626 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012006626 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120323 |